Aarti Drugs Limited has informed the Exchange about re-appointment of Director and appointment of Secretarial Auditor at AGM
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
At the 40th Annual General Meeting held on September 24, 2025, shareholders of Aarti Drugs approved two items. First, the re-appointment of Shri Harshit Manilal Savla (DIN: 00005340) as Joint Managing Director, who was liable to retire by rotation. He has been with the company since 1987 and brings over 38 years of experience in finance, exports, and administration, having played a key role in expanding the company's API and formulation businesses. Second, the appointment of M/s. Mehta & Mehta, Practicing Company Secretaries, as the new Secretarial Auditor for a five-year term covering FY2025-26 through FY2029-30. The filing also confirms that Savla is not debarred from accessing capital markets or holding the office of director by any regulatory authority.
This is a routine corporate governance update with no material impact on shareholders. The re-appointment of an experienced long-serving director signals continuity in management, and the appointment of a new secretarial auditor for a five-year term is a standard compliance requirement.